AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01956734 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DNX2401 and Temozolomide
Description: Virus injection in the brain parenchyma after pathology confirmation of recurrent glioblastoma.~Temozolomide oral 14 days after virus injection.
Study NCT05378646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon gamma human recombinant (IFN-G)
Description: received by microbiological synthesis; specific antiviral activity on cells is 2x10\*7 Units per mg of protein
Study NCT01165372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artesunate or dihydroartemisinin-piperaquine
Description: artesunate 2mg/kg/day, artesunate 4mg/kg/day or dihydroartemisinin-piperaquine once daily
Study NCT00929604 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIV-1 viral load testing
Description: Plasma HIV-1 RNA viral load testing performed at ART initiation (baseline) and at 3, 6, 12, 18, 24, 30, and 36 months thereafter. Routine viral load results are provided to clinicians for the management of the participant's HIV treatment.
Study NCT00698204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib
Description: Subject was asked to take celecoxib each day that radiation therapy was given.
Study NCT00698204 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Subject was asked to take placebo each day that radiation therapy was given.
Study NCT02290860 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Type 2 diabetes diagnosis test
Description: Participants will perform type 2 diabetes diagnosis test the day of hospital discharge after delivery and the same test around 8 weeks later.
Study NCT02224599 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TAPA-pulsed DC vaccine
Description: Subjects will given the vaccine which contains 1 x 10\^7 TAPA-pulsed dendritic cells and is administered ID. A total of three (3) cycles therapy will be administered weekly.
Study NCT02224599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide Pill
Description: Subjects will be given low-dose cyclophosphamide by mouth for 5 days starting 5 to 7 days prior to the vaccine cycle.
Study NCT02224599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod Topical Cream
Description: Topical Imiquimod Cream will be applied after vaccination.
Study NCT00314249 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, oral administration, twice daily for 12 weeks
Study NCT00314249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milnacipran 100mg
Description: Milnacipran 100mg per day (50mg BID \[twice a day\])
Study NCT03120806 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Interrupted subcuticular skin closure
Description: skin is closed with interrupted mattress subcuticular sutures using non-absorbable polypropylene after elective cesarean section
Study NCT03120806 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: continuous subcuticular skin closure
Description: skin is closed with continuous subcuticular sutures using non-absorbable polypropylene after elective cesarean section
Study NCT00868426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide/Formoterol Batch 1
Description: Single, inhaled dose
Study NCT00868426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide/Formoterol Batch 2
Description: Single, inhaled dose
Study NCT00868426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide/Formoterol Batch 1 and charcoal
Description: Single, inhaled dose
Study NCT02067442 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral acetaminophen
Description: 1000 milligrams given orally before surgery
Study NCT02067442 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravenous acetaminophen
Description: 1000 milligrams of intravenous acetaminophen given before surgery
Study NCT04532216 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arthroscopic-Assisted Acromioclavicular Joint Reconstruction Using the TightRope Device
Description: Arthroscopic-assisted AC joint reconstruction with the TightRope device with allograft augmentation and with the patient in the lateral decubitus position is a method of restoring joint stability
Study NCT04532216 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Traditional surgery
Description: Tendon transfer
Study NCT04679753 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Brainsway DTMS with intermittent Theta Burst Stimulation (iTBS)
Description: Brainsway DTMS with iTBS
Study NCT04679753 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Brainsway DTMS with High Frequency (HF) Stimulation
Description: Brainsway DTMS with HF
Study NCT02316184 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational Interviewing
Description: Motivational Interviewing is a client-centered method of exploring individual's interest in making behavioral changes. In this study, the targeted behavior is alcohol use.
Study NCT02316184 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Brief Advice
Study NCT01672567 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Egg supplementation
Description: Daily consumption of 2 eggs for breakfast for 6 weeks
Study NCT01672567 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Egg substitute
Description: Daily consumption of 1/2 cup of Egg Beater for breakfast for 6 weeks
Study NCT01672567 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Control diet
Description: Daily consumption of high carbohydrate breakfast diet for 6 weeks, consisting of any of the following choices during each day of the treatment period: bagel, waffles, pancakes, or cereal and milk
Study NCT01092975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: phenylephrine solution
Description: Subjects will receive up to 40 dose of topical phenylephrine at the specified dose level.
Study NCT00144612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRA(Tocilizumab)
Description: 8mg/kg/2weeks
Study NCT04434196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-99282
Description: CC-99282
Study NCT04434196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab
Study NCT03747978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perindopril and Amlodipine
Description: Fixed combination of Perindopril 5mg and Amlodipine 5mg
Study NCT03747978 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Perindopril-indapamide
Description: Perindopril 5mg and Indapamide 1.25mg
Study NCT00057356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: conivaptan
Description: IV
Study NCT00057356 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: IV
Study NCT00780013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin hydrochloride liquid 500 mg per 5 mL
Study NCT00780013 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin hydrochloride liquid 500 mg per 5 mL
Study NCT01805960 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Canakinumab
Study NCT01805960 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03706495 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Group I Postural Exercise
Description: Spine anatomy and daily life activities will be informed about proper posture. Strengthening of postural muscles, stretching (Pectoral Region, M. Psoas Major) and breathing exercise will be performed under the supervision of a physiotherapist. The Group I will receive postural exercise for 60 min/day 2 times/week for 8 weeks.
Study NCT03706495 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Group II Three-dimensional Exercise Therapy Program
Description: The Group II Schroth method corrects the kyphotic posture, with the help of proprioceptive and exteroceptive stimulation and mirror control in the sagittal plane, using specific corrective breathing patterns. The Schroth method three-dimensional exercise therapy program adapted for the specific posture will be exercised in four specific positions (sitting, supine, standing, prone) under the supervision of a physiotherapist. Exercise include, trunk elongation, symmetrical sagittal straightening, shoulder traction, corrective breathing and muscle activation by increasing tension (isometric tension). The Group II will receive Schroth's three-dimensional exercise therapy program for 60 min/day 2 times/week for 8 weeks.
Study NCT04323085 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Speech-in-Noise Treatment Program
Description: Speech therapy program for hypophonia.
Study NCT04323085 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Speech-to-Noise Feedback Device Program
Description: Speech Feedback device program for hypophonia.
Study NCT00344565 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Modafinil
Description: During the first lead-in week, participants will attend the clinic 3 times per week, participate in one session of neuropsychological assessment and receive motivational interviewing and Cognitive Behavioral Therapy--Relapse Prevention (CBT-RP). At the end of the first lead-in week participants will be randomized to modafinil or placebo stratified by the levels of cocaine use, and whether or not abstinence was achieved. Participants will then be followed for 11 weeks with measures of cocaine cravings and withdrawal, and drug use outcome, and will receive CBT-RP.
Study NCT00344565 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Modafinil
Description: During the first lead-in week, participants will attend the clinic 3 times per week, participate in one session of neuropsychological assessment and receive motivational interviewing and Cognitive Behavioral Therapy--Relapse Prevention (CBT-RP). At the end of the first lead-in week participants will be randomized to modafinil or placebo stratified by the levels of cocaine use, and whether or not abstinence was achieved. Participants will then be followed for 11 weeks with measures of cocaine cravings and withdrawal, and drug use outcome, and will receive CBT-RP.
Study NCT00344565 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy--Relapse Prevention
Description: Once weekly individual session of motivational interviewing and Cognitive Behavioral Therapy--Relapse Prevention (CBT-RP)
Study NCT00344565 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive Behavioral Therapy--Relapse Prevention
Description: Once weekly individual session of motivational interviewing and Cognitive Behavioral Therapy--Relapse Prevention (CBT-RP)
Study NCT05573776 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Therapy, High Protein supplement
Description: patients with gastric and pancreatic cancer will be eligible, and 30 patients will be randomly assigned to the exercise therapy + high protein supplement group and 30 patients to the exercise therapy + placebo supplement group.
Study NCT02882542 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visible light exposure
Description: Subjects will be exposed to visible colored light for 15 minutes. The visible light will be generated by red-green-blue light emitting diodes light cans.
Study NCT00401739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CSL360
Description: Weekly IV Infusion. Dose escalation study.
Study NCT04142528 — intervention group
Intervention type: DEVICE
Intervention: ParkinPal
Description: Wear and periodic recording of motion data during daily wear
Study NCT02265861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCG
Study NCT03042182 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oral therapeutic vaccine V3-X to treat cholangiocarcinoma
Description: One single pill of V3-X vaccine administered once per day to patients with cholangiocarcinoma
Study NCT00779922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Study NCT01591525 — intervention group
Intervention type: BEHAVIORAL
Intervention: Education on Type II Diabetes
Description: one-on-one education about having Type II Diabetes, the possible complications and treatment options provided by a physician.
Study NCT04213027 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: native tissue repair procedures with conventional surgical instruments
Description: Sacrospinous ligament fixation (SSLF): treatment for apical prolapse with vaginal fornix suspended to sacrospinous ligament; Ischial spinous fascia fixation (ISFF): treatment for apical prolapse with vaginal fornix suspended to ischial spinous fascia (ISFF).
Study NCT03599037 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ICOUGH Recovery App v2.0
Description: The app has pre-set auditory, visual reminders, in the form of push notifications, that remind participants to use the incentive spirometer and ambulate around the hospital at time intervals recommended by the ICOUGH protocol. The app benchmarks the level of adherence to that of other subjects involved in the study via the My Summary page, and this visual anonymous comparison further motivates adherence to the ICOUGH protocol.
Study NCT00902187 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Fesoterodine
Description: A fesoterodine extended-release tablet (ER) formulation once daily administration of 4 mg
Study NCT00795249 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: smoking cessation
Description: After baseline examination, the group is asked to quit smoking for 2 weeks.
Study NCT01643525 — intervention group
Intervention type: DEVICE
Intervention: Nautilus NeuroWaveTM System
Description: Non-invasive device designed to detect pressure signals from the skull to aid in the diagnosis of ischemic stroke.
Study NCT02933632 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy-SAP
Description: * Day 1) Patients started approach after discharged anesthesia. Patients received verbal orientation and demonstration of the physiotherapy exercises that would strengthen muscles (gluteal and thigh). They were oriented to the decubitus changes and how to leave bed. They practiced 3 repetitions of 12 complete movements for each exercise;~* Day 2) Patients repeated the exercises learned from day 1. Following the proposed activities patients received verbal instructions on gait training and then starting gait training. Patients started gait training on this second day only if they felt safe and claimed that their pain was controlled. Otherwise, training was postponed to the next day;~* Day 3) Patients repeated the day 2. And the patient who had not started gait training in the day 2, began it on the day 3;~* Day 4 and other days) Patients repeated the gait training until the discharge date.
Study NCT02933632 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy-ARP
Description: * Day 1-1°approach) Patients started after discharged anesthesia. Received verbal orientation and demonstration of the physiotherapy exercises that would strengthen muscles (gluteal and thigh). They were oriented to the decubitus changes and how to leave bed. They practiced 3 repetitions of 12 complete movements for each exercise;~* Day 1-2°approach) Patients repeated the exercises learned from day 1-1°approach. Following patients received verbal instructions on gait training and then starting gait training. Patients started gait training on this Day 1-2°approach only if they felt safe and claimed that their pain was controlled. Otherwise, training was postponed to next approach;~* Day 1-3°approach) Patients repeat the day 1-2°approach. And the patient, who had not started gait training in the day 1 - second approach, began it in this third approach;~* Day 2) Patients repeated three times the day 1-3°approach;~* Day 3) Patients repeated three times the day 1-3°approach.
Study NCT02004951 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Misago RX
Study NCT02004951 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Zilver PTX
Study NCT00072358 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-GD2 murine IgG3 monoclonal antibody 3F8
Description: The total dosage of 3F8 per cycle is the same as in prior trials (100 mg/m2), administered at 20 mg/m2/day and infused over \~1.5 hr or less (0.5 hr is customary), with analgesics and antihistamines used as needed for expected side-effects. 3F8 is started \~1 hr after completion of GM-CSF administration. GM-CSF is dosed at 250 mcg/m2/day from day -5 to day +1 (Wednesday to Tuesday is customary) , and is 500 mcg/m2/day thereafter (i.e., on days +2 to +4; Wednesday to Friday), as in the predecessor protocol.18,74 Patients come off study if progressive disease occurs or if there is life-threatening grade 4 toxicity from 3F8; otherwise, patients will receive a minimum of 4 cycles of treatment and will continue treatment through 24 months. It is expected that patients will receive \~10 cycles.
Study NCT01534013 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Imperial College Closed-Loop Insulin Delivery System
Description: The Imperial College closed-loop insulin delivery system comprises 3 main components: the glucose sensor, the control algorithm and the insulin delivery system.
Study NCT01534013 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Open loop
Description: glucose sensor and pump
Study NCT01085786 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 14-day sequential treatment
Description: * 14-day sequential therapy arm: esomeprazole 40 mg and amoxicillin 1 g twice daily for 7 days followed by esomeprazole 40 mg, clarithromycin 500 mg and metronidazole 500 mg twice daily for 7 days~* 14-day hybrid therapy arm: esomeprazole 40 mg and amoxicillin 1 g twice daily for 7 days followed by esomeprazole 40 mg, amoxicillin 1 g, clarithromycin 500 mg and metronidazole 500 mg twice daily for 7 days
Study NCT01085786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 14-day hybrid treatment
Description: esomeprazole 40 mg and amoxicillin 1 g twice daily for 7 days followed by esomeprazole 40 mg, amoxicillin 1 g, clarithromycin 500 mg and metronidazole 500 mg twice daily for 7 days
Study NCT00136409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib mesylate
Description: 400mg orally once daily until disease progression or unacceptable side effects
Study NCT03889665 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Suspension training
Description: Nine sessions of suspension training The suspension device will be TRX (R) The intervention will be administered in work:rest intervals (2:1) A global training approach will seek to train lower limbs, upper body and core musculature
Study NCT03372850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HIP1601
Description: Test Drug
Study NCT03372850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP1705
Description: Reference Drug
Study NCT05829642 — intervention group
Intervention type: BEHAVIORAL
Intervention: Enhanced Care Management
Description: ECM aims to enable primary health care providers to coordinate care for patients with complex medical needs. It involves the close coordination of services across all treatment modalities and clinical team members, including primary care physicians, specialists, pharmacists, and other healthcare professionals. Providers undertake:~Comprehensive care planning: A comprehensive care plan is developed and updated by all members of the patient's healthcare team, including their primary care physician, specialist, and other providers, to ensure that all aspects of treatment are addressed.~Proactive outreach: Outreach activities, such as phone calls, home visits, and other forms of contact with the patient and their family are also used to promote patient engagement in health management~Monitoring: Close monitoring of patients and their health conditions is essential to ensure that treatments are effective and that any adverse effects are quickly identified and addressed
Study NCT01379573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Nineteen women meeting eligibility criteria will receive 400mg per day of HCQ beginning as soon as pregnancy is established and informed consent obtained. Mothers already on HCQ will remain on 400mg, or escalate to 400mg if on 200mg. Hydroxychloroquine is taken in 200mg pill form - 400mg = 2 200mg pills.
Study NCT02794142 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: renal transplantation
Study NCT02794142 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No intervention
Study NCT02247245 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivabradine
Description: Ivabradine 7.5mg
Study NCT02247245 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Atrial fibrillation
Description: Pacemaker base rate alteration
Study NCT02247245 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00744211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1mg/kg sitaxsentan sodium
Description: 1mg/kg sitaxsentan sodium (intravenous bolus) performed immediately before separation from cardiopulmonary bypass and again at 12 hours after cardiopulmonary bypass.
Study NCT00744211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2mg/kg sitaxsentan sodium
Description: 2mg/kg sitaxsentan sodium (intravenous bolus) performed immediately before separation from cardiopulmonary bypass and again at 12 hours after cardiopulmonary bypass.
Study NCT00744211 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Intravenous bolus performed immediately before separation from cardiopulmonary bypass and again at 12 hours after cardiopulmonary bypass.